To the full analysis
Emergent BioSolutions stock: growth
EBSEmergent BioSolutions reported $742.9M in revenue for fiscal 2025, down 28.8% on the prior year, down 14% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
8.7%
per year from 2006 to 2025, per share 4%
Earnings (Annual rate)
4.5%
per year from 2006 to 2025, per share −0.1%
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2006 | |
|---|---|---|---|
| Revenue | −14.0% | 4.3% | 8.7% |
| Revenue per share | −14.2% | 0.9% | 4.0% |
| Earnings | −29.7% | −1.8% | 4.5% |
| Earnings per share | −29.9% | −5.0% | −0.1% |
| Free cash flow | −16.9% | no data | no data |
| Free cash flow per share | −17.1% | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2006 | $152.73M | $22.79M | −$45.29M |
| 2007 | $182.92M | $22.94M | $11.48M |
| 2008 | $178.55M | $20.68M | −$13.5M |
| 2009 | $234.79M | $31.14M | −$2.78M |
| 2010 | $286.17M | $51.7M | $77.44M |
| 2011 | $273.38M | $23.02M | −$39.43M |
| 2012 | $281.89M | $23.52M | −$14.2M |
| 2013 | $312.75M | $31.14M | $54.95M |
| 2014 | $404.47M | $36.74M | $81.65M |
| 2015 | $489.33M | $62.87M | −$353K |
| 2016 | $488.8M | $51.8M | −$22.77M |
| 2017 | $560.9M | $82.6M | $153.31M |
| 2018 | $782.4M | $62.7M | −$30.3M |
| 2019 | $1.11B | $54.5M | $101.1M |
| 2020 | $1.58B | $305.8M | $395M |
| 2021 | $1.77B | $219.5M | $96.1M |
| 2022 | $1.12B | −$211.6M | −$149.9M |
| 2023 | $1.05B | −$760.5M | −$257.9M |
| 2024 | $1.04B | −$190.6M | $35.8M |
| 2025 | $742.9M | $52.6M | $156.8M |
Revenue by segment
How Emergent BioSolutions Inc. makes its money and how that has shifted. Names are as the company reports them.
- Product$705.2M95%
- Contracts and Grants$37.7M5%
The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| Product | $705.2M | 94.9% |
| Contracts and Grants | $37.7M | 5.1% |
| Total revenue | $742.9M | 100% |
Revenue by region
Where Emergent BioSolutions Inc. generates its revenue.
- United States$531.1M71%
- Canada$75.0M10%
- Other$136.8M18%
“Other” combines smaller regions with revenue the company does not assign to a region. The company split earlier years differently. A history would not be comparable, so only 2025 is shown.
Figures as a table
| 2025 | Share 2025 | |
|---|---|---|
| United States | $531.1M | 71.5% |
| Canada | $75M | 10.1% |
| Other | $136.8M | 18.4% |
| Total revenue | $742.9M | 100% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 27 Feb 2026)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.